AXSM stock forecast, quote, news & analysis
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more
Why Axsome Therapeutics (AXSM) Stock Is Down -19% in the Last 30 Days
Key Takeaways
- Axsome Therapeutics (AXSM) fell roughly 19% over the past 30 days, sliding from about $179 to near $144 by late October 2026.
- The decline reflects investor concern that commercial launches of its central nervous system (CNS) therapies—particularly Auvelity's Alzheimer's agitation indication—are tracking below the elevated expectations previously priced into the stock.
- Several firms trimmed price targets during the period, including RBC Capital, Deutsche Bank, Morgan Stanley, and Piper Sandler, while insider selling added to selling pressure.
- Broader risk-off sentiment in biotech and institutional de-grossing compounded the move, even as the company's revenue growth remained strong.
- Over the last quarter, the stock is down roughly 30%, extending a pullback from its mid-2026 all-time high.
- Investors can find additional detail on Price Targets, Earnings, and Forecast on dedicated pages for deeper analysis.
- Traders looking for systematic signals can explore Trending AI Robots to see curated, top-performing automated strategies.
Axsome Therapeutics (AXSM) Company Overview and Market Position
Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on developing and marketing treatments for central nervous system disorders. Its approved portfolio includes Auvelity (dextromethorphan-bupropion), indicated for major depressive disorder and for agitation associated with dementia due to Alzheimer's disease; Sunosi (solriamfetol), used for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea; and Symbravo (meloxicam-rizatriptan) for migraine. The company also advances a pipeline that includes AXS-05, AXS-12, and AXS-14 across indications such as Alzheimer's disease agitation, narcolepsy, and fibromyalgia. Investors follow the stock closely because of Axsome's rapid revenue growth and the large addressable CNS markets it targets, even though the company remains unprofitable.
Axsome Therapeutics (AXSM) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, Axsome shares declined approximately 19%, falling from a close near $179 in early October to about $144 by late October 2026. The move was marked by an extended stretch of consecutive down sessions and a drop below key short- and longer-term moving averages. The broader quarterly picture is even weaker: the stock is down roughly 30% over the last three months and has retreated sharply from its mid-2026 all-time high. This sustained downtrend contrasts with the broader market, which advanced modestly over the same window, underscoring that much of the pressure has been company- and sector-specific rather than driven by broad equity weakness.
What Drove AXSM Stock Price in the Last 30 Days
The primary catalyst has been disappointment around the commercial launch trajectory of Axsome's key CNS products. Investors had priced in aggressive growth assumptions, and early prescription trends for Auvelity's Alzheimer's agitation indication fell short of those expectations. This prompted a series of analyst price-target reductions: RBC Capital lowered its target to $295 from $297, Deutsche Bank cut to $267 from $280, Morgan Stanley trimmed to $247 from $251, and Piper Sandler reduced its target to $238 from $258. Insider transactions added further pressure, with the chief executive officer and chief operating officer reporting share sales during the period. A broader risk-off tone toward small- and mid-cap biotech, alongside institutional position reductions, compounded the decline even as the company's underlying revenue growth remained robust.
What Drove AXSM Stock Performance Over the Last Quarter
The quarterly decline is part of a longer de-rating that began after the stock reached an all-time high in mid-2026. Over several months, investor sentiment shifted as commercial launch expectations for Axsome's newer indications were reset lower across the sector. A more challenging interest-rate environment favored larger, cash-generative names over smaller, cash-burning developers, while the biotechnology sector saw meaningful bifurcation. Within Axsome specifically, concerns about how quickly new products can scale, combined with ongoing operating losses and significant debt, led investors to reassess the premium previously attached to the shares. The science and market opportunities remain intact, but the market has repriced the stock to reflect a more measured view of execution risk.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of automated trading strategies across the platform. Tickeron provides hundreds of AI trading bots that collectively monitor thousands of tickers, but only the top-performing and most relevant bots appear in this dedicated section. The featured robots vary widely in their underlying strategy, trading timeframe, and performance metrics, allowing users to evaluate approaches that suit different objectives and risk profiles. Because the selection is updated to reflect current performance and market relevance, the page serves as a practical starting point for investors interested in systematic, data-driven trading signals alongside their own research.
AXSM Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will focus on the company's third-quarter results, which Axsome has said it will report in early November 2026, including revenue growth and any updated commentary on Auvelity prescription trends and the Alzheimer's agitation launch. Additional factors to monitor include progress on the broader pipeline, further analyst rating or price-target revisions, insider activity, and the direction of interest rates, which influence sentiment toward unprofitable biotech names. Competitive dynamics in CNS markets and broader sector rotation between large- and small-cap biotech will also shape the stock's path. These developments should be evaluated alongside individual risk tolerance rather than treated as a basis for any investment decision.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AXSM's RSI Oscillator climbs out of oversold territory
The RSI Indicator for AXSM moved out of oversold territory on November 10, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 52 cases where AXSM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for AXSM just turned positive on November 09, 2026. Looking at past instances where AXSM's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
Following a +6.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXSM advanced for three days, in 237 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
AXSM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for AXSM moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for AXSM entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 52 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. AXSM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AXSM's P/B Ratio (83.233) is slightly higher than the industry average of (3.498). P/E Ratio (-35.299) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (13.908) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services for pain and other nervous system
Industry Biotechnology